Dr. Heyman on the Evolution of BTK Inhibitors in Relapsed/Refractory MCL

Video

In Partnership With:

Benjamin Heyman, MD, discusses the evolution of BTK inhibitors in relapsed/refractory mantle cell lymphoma.

Benjamin Heyman, MD, assistant clinical professor, Medicine, hematologist, Moores Cancer Center, University of California, San Diego Health, discusses the evolution of BTK inhibitors in relapsed/refractory mantle cell lymphoma (MCL).

The introduction of single-agent BTK inhibitors transformed the treatment of patients with relapsed/refractory MCL, Heyman says. Long-term data with single-agent ibrutinib (Imbruvica) demonstrated an overall response rate of approximately 70% and complete response rate of approximately 30%. However, responses appear to be dependent on timing of treatment. For example, patients with 1 prior line of therapy have superior responses compared with those who received 2 or more prior lines of therapy, Heyman explains.

The second-generation covalent BTK inhibitors acalabrutinib (Calquence) and zanubrutinib (Brukinsa) are also FDA approved for use in patients with relapsed/refractory MCL, Heyman says. Without cross-trial comparisons, it is difficult to determine whether these agents demonstrate improved efficacy vs ibrutinib; however, acalabrutinib and zanubrutinib are associated with less hematologic adverse effects and reduced risk of cardiovascular toxicities compared with ibrutinib, Heyman says.

Additionally, noncovalent BTK inhibitors, such as pirtobrutinib (LOXO-305), as well as combination regimens with ibrutinib and venetoclax (Venclexta) or CD20-directed monoclonal antibodies appear to be promising strategies to improve response rates, outcomes, and duration of response, Heyman concludes.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,